Dr. Peter Hotez on the Joe Rogan Experience #1451, fact-checked

What the evidence shows: Hotez, speaking on April 1, 2020, asserted that COVID-19 is five to ten times more lethal than seasonal influenza. This tracked contemporaneous, case-fatality-based comparisons: a JAMA Internal Medicine analysis (Faust & del Rio, May 2020) found New York City's COVID-19 case fatality rate roughly 9.5 times higher than a severe seasonal flu comparator, though the authors cautioned the comparison was imprecise given differences in testing and reporting. As broader seroprevalence testing later revealed many more mild and asymptomatic SARS-CoV-2 infections than initially counted, population-wide infection fatality rate (IFR) estimates fell substantially. A widely cited meta-analysis of worldwide seroprevalence studies (Ioannidis, Bulletin of the World Health Organization, 2021) put the median COVID-19 IFR at about 0.23-0.27% (about 0.05% in people under 70), compared with a commonly cited seasonal influenza IFR of roughly 0.1%. Under this later, more complete accounting, COVID-19's overall lethality relative to flu is generally estimated at roughly two to three times higher rather than five to ten times, though the ratio varies considerably by age, location, and time period, and was substantially higher earlier in the pandemic and in older populations. The claim reflects a reasonable early-pandemic estimate given the data available at the time, but later, broader data showed it was on the high end to overstated once the true scale of mild and undetected infections became clear.

What the evidence shows: Hotez was likely referring to the CDC's March 18, 2020 MMWR report on COVID-19 outcomes in the U.S. through March 16, 2020, which found that adults aged 20-44 accounted for about 20% of hospitalizations (range 14.3%-20.8% given missing data), not a third. That same age group made up a smaller share of ICU admissions (12% of ICU cases, and only 2%-4% of the age group's own cases required ICU care) and a much smaller share of deaths (0.1%-0.2% case-fatality) compared with older age brackets, where severity rose sharply with age; 80% of deaths occurred in adults 65 and older. The report did note that severe illness including hospitalization and ICU admission could occur in adults of any age, which was the underlying point Hotez was making, but the specific "about a third" figure overstates the actual 20-44 hospitalization share and elides the much lower rate of severe outcomes (ICU admission, death) in that age group relative to hospitalization alone. The underlying CDC data also carried substantial uncertainty, since hospitalization, ICU, and outcome status were unknown for a large share of the 4,226 cases analyzed. The general point that younger adults were not immune to severe COVID-19 is well-supported, but the specific "a third" statistic as stated is a misleading rounding-up of the actual reported figures.

What the evidence shows: The study Hotez references is Dong et al., published in Pediatrics (March 2020), which reported that 40 of 379 infants (under age 1) among 2,143 pediatric COVID-19 cases in China were classified as severe or critical, a raw proportion of about 10.6%, matching the "10%" figure cited. A subsequent peer-reviewed commentary (Salemi et al., Early Human Development, 2020) found this raw proportion overstates true illness severity because it was not adjusted for case underascertainment: many mild or asymptomatic infections in the broader population were never tested or counted, inflating the apparent severity rate among the cases that were captured. After correcting for underascertainment using published epidemiological modeling, the same commentary recalculated the severity proportion for infants at 40/3,662, or about 1.1%, roughly a tenfold reduction from the raw 10.6% figure. The Dong et al. study itself also noted that two-thirds of the pediatric cases were "suspected" rather than laboratory-confirmed, and that suspected cases had more than twice the severity rate of confirmed cases (7.4% vs 2.6%), suggesting some illnesses attributed to COVID-19 may have had other causes. The claim is traceable to a real number in the cited study but presents an uncorrected, likely overestimated statistic as an established finding about infant illness severity.

What the evidence shows: Hotez's four-to-ten-times-flu figure, made in early 2020, matched estimates that several public-health experts were citing at the time (a March 2020 NPR report quoted a similar 5-to-10-times-flu range), so it reflected a real if provisional strand of expert opinion rather than a fringe claim. However, those early estimates relied on crude case-fatality-rate calculations from limited, symptomatic-biased testing data, and epidemiologists including John Ioannidis warned contemporaneously (STAT News, March 17, 2020) that the true infection fatality rate was highly uncertain and could be far lower once undetected mild and asymptomatic infections were counted. Later seroprevalence-based analysis (Ioannidis, Bulletin of the World Health Organization, 2021) found a global median COVID-19 infection fatality rate of about 0.27% (0.23% corrected), which the study explicitly describes as "much lower than estimates made earlier in the pandemic." Seasonal influenza's infection fatality rate is typically estimated around 0.1%, so the best subsequent evidence puts COVID-19's overall lethality multiplier at roughly two to three times flu in the general population, well below the four-to-ten-times figure Hotez cited, though rates were and remain much higher than that in older and high-risk groups. The claim's underlying death-toll math also did not fully anticipate later mitigating factors (behavior change, treatment improvements, vaccines) or the extent of under-ascertainment of mild cases, and was in that sense exaggerated relative to how the pandemic ultimately unfolded, even though it was consistent with genuine uncertainty and some expert views current in March 2020.